References
- Muretta JM, Mastick CC. How insulin regulates glucose transport in adipocytes. Vitam Horm 2009;80:245–286.
- Zou C, Wang Y, Shen Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J Biochem Biophys Methods 2005;64:207–215.
- Hardie DG. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 2008;582:81–89.
- Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21:687–710.
- Hernandez R, Teruel T, de Alvaro C, Lorenzo M. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 2004;47:1615–1624.
- Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125–2135.
- Bozdag O, Verspohl EJ, Ertan R. Synthesis and hypoglycemic activity of some new flavone derivatives. 2nd communication: 4′-flavonyl-2,4-thiazolidinediones. Arzneimittelforschung 2000;50:539–543.
- Bozdag O, Verspohl EJ, Ertan R. Synthesis and hypoglycemic activity of some new flavone derivatives. 3rd communication: 3′-flavonyl-2,4-thiazolidinediones. Arzneimittelforschung 2000;50:626–630.
- Bozdag-Dündar O, Waheed A, Verspohl EJ, Ertan R. Synthesis and hypoglycemic activity of some new flavone derivatives. 4th communication: 6-flavonyl-2,4-thiazolidinediones. Arzneimittelforschung 2001;51:623–627.
- Tunçbilek M, Bozdag-Dündar O, Ayhan-Kilcigil G, Ceylan M, Waheed A, Verspohl EJ et al. Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives–fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones. Farmaco 2003;58:79–83.
- Bozdag-Dündar O, Verspohl EJ, Das-Evcimen N, Kaup RM, Bauer K, Sarikaya M et al. Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg Med Chem 2008;16:6747–6751.
- Bozdag-Dündar O, Verspohl EJ, Waheed A, Ertan R. Synthesis and antidiabetic activity of some new furochromonyl-2,4-thiazolidinediones. Arzneimittelforschung 2003;53:831–836.
- Bozdag-Dündar O, Ceylan-Unlüsoy M, Verspohl EJ, Ertan R. Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones. Arzneimittelforschung 2007;57:532–536.
- Verspohl EJ, Bozdağ-Dündar O, Kaup RM, Bauer K, Ertan R. Insulinotropic activity of chromonyl-2,4-thiazolidinediones. Med Chem Res 2009;18:665–670.
- Bozdag-Dündar O, Ceylan-Unlüsoy M, Verspohl EJ, Ertan R. Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring. Arzneimittelforschung 2006;56:621–625.
- Bozdag-Dündar O, Mentese A, Verspohl EJ. Synthesis and antidiabetic activity of some new thiazolyl-2,4-thiazolidinediones. Arzneimittelforschung 2008;58:131–135.
- Lima MC, Costa DL, Goes AJ, Galdino SL, Pitta IR, Luu-Duc C. Synthesis and antimicrobial activity of chlorobenzyl benzylidene imidazolidinedione derivatives and substituted thiazolidinediones. Pharmazie 1992;47:182–184.
- Athmani S, Farhat MF, Iddon B. Azoles. Part 9. Synthesis of derivatives of thieno [2,3-d]thiazole, 4H-pyrrolo-2,3-d]thiazole, 2H-pyrazolo[3,4-d]thiazole and isoxazole [3,4-d]thiazole from thiazolidine-2,4-dione. J Chem Soc Perkin Trans 1 1992;973–977.
- Debski N, Hanefeld W, Schlitzer M. Improved Synthesis of 2-Substituted 4-Chlorothiazole-5-carbaldehydes. J Heterocyclic Chem 1997;34:1427–1429.
- Rida SM, Salama HM, Labouta IM, A-Ghany YS. Synthesis of some 3-(benzimidazol-2-ylmethyl)thiazolidinone derivatives as potential antimicrobial agents. Pharmazie 1985;40:727–728.
- Lo C, Shropshire EY. The Alkylation of 2,4-Thiazolidinedione. J Org Chem 1957;22:999–1001.
- Costa DLB, Chantarel J, DeLima MCA, Albuquerque JFC, Lima RMO, Galdino SL, Pitta IR, Luu-Duc C. Imidazolidinediones et thiazolidinediones substituées: synthèse, étude structurale et activité cytotoxique. J Pharm Belg 1995;50:5–10
- Salama HM, Labouta IM, Moustafa MA. Synthesis and in vitro antimicrobial evaluation of some 5-substituted-3-phenacylthiazolidine-2,4-diones. Alex J Pharm Sci 1990;4:44–46.
- de Lima JG, Perrissin M, Chantegrel J, Luu-Duc C, Rousseau A, Narcisse G. Synthesis and pharmacological evaluation of some 3-phenacyl-5-benzylidene-thiazolidine-2,4-diones. Arzneimittelforschung 1994;44:831–834.
- Albuquerque JF, Albuquerque A, Azevedo CC, Thomasson F, Galdino LS, Chantegrel J et al. Substituted thiazolidinediones and thio-imidazolidinones: synthesis, structural study and pharmacological activity. Pharmazie 1995;50:387–389.
- Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992;130:167–178.
- Yoshioka K, Takahashi H, Homma T, Saito M, Oh KB, Nemoto Y et al. A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim Biophys Acta 1996;1289:5–9.
- Bozdag-Dündar O, Ozgen O, Mentese A, Altanlar N, Atli O, Kendi E et al. Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives. Bioorg Med Chem 2007;15:6012–6017.
- Ishida T, In Y, Inoue M, Tanaka C, Hamanaka N. Conformation of (Z)-3-carboxymethyl-[(2E)-2-methyl-3-phenylpropenylidene]rhodanine (epalrestat), a potent aldose reductase inhibitor: X-ray crystallographic, energy calculational, and nuclear magnetic resonance studies. J Chem Soc Perkin Trans II 1990;1085–1091.